What’s the Secret Recipe? Treating Depression with TMS in the Era of Accelerated Protocols and Functional MRI Targeting

You are invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: What’s the Secret Recipe? Treating Depression with TMS in the Era of Accelerated Protocols and Functional MRI Targeting featuring Nicholas T. Trapp, MD.

Methods for enhancing the antidepressant effects and treatment efficiency of transcranial magnetic stimulation have advanced rapidly in the past several years, with new FDA-cleared protocols and promising early data. Dr. Trapp will discuss the evidence for various TMS optimization procedures with a focus on trying to understand the “secret recipe” for delivery of the most efficacious TMS treatment protocol.

During this presentation participants will:

• Discuss current methods and considerations for TMS targeting of the DLPFC for depression treatment.
• Discuss current evidence for dose-response effects and accelerated TMS protocols for depression.
• Review methods and data for optimizing the antidepressant effects of TMS.

Take advantage of our live Q&A session at the conclusion of the webinar.

Date: July 2, 2024 at 8:00 pm EST | 5:00 pm PST | 1:00 am GMT

Format: Live Webinar

Cost: Members: $25 | Non-members $50 | Student Members FREE

Can't make this time and date? All Grand Rounds are recorded and available On-Demand to all registered attendees. Recordings are available Friday after the live event.

Speaker: Nicholas T. Trapp, MD

Dr. Trapp is an Assistant Professor of Psychiatry at the University of Iowa, where he is the Director of the Interventional Psychiatry Program and the Neuropsychiatry Clinic.  He completed psychiatry residency at Washington University in St. Louis, followed by post-doctoral fellowship in neurostimulation and neuroimaging at the University of Iowa and behavioral neurology/neuropsychiatry at Stanford University. His research focuses on the targeting, application, and optimization of neuromodulation therapies for the treatment of psychiatric conditions. Projects have included novel TMS clinical trials, mechanistic TMS studies, and lesion-network mapping of psychiatric symptoms to identify candidate brain stimulation targets. He also leads the TMS for Depression Consensus Recommendations Work Group as part of the National Network of Depression Centers Neuromodulation Task Group and serves on the Clinical TMS Society Research Committee. Clinically Dr. Trapp evaluates patients for TMS, ECT, DBS, VNS, and esketamine.  He has received Career Development Awards from the National Institutes of Mental Health and the American Neuropsychiatric Association, as well as a Young Investigator Award from the Brain and Behavior Research Foundation. His current research funding is to study the electrophysiologic effects of TMS in epilepsy patients with intracranial recording electrodes.